Clarissa Sowemimo-Coker

Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom.

Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom.

Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom.